The University of California inventors were removed from U.S. patent number 6,777,231, which was licensed to Cytori Therapeutics (NASDAQ: CYTX). The decision was made today by the United States District Court in the Central District of California.

The ‘231 patent covers isolated adipose-derived stem cells and does not affect Cytori’s commercialization of the Celution^® System or the Company’s product pipeline. However, Cytori believes that the court’s decision is incorrect and that the University of California may elect to appeal the ruling.

Cytori was recently granted a foundational patent on its Celution^® System device technology for processing a mixture of adult stem and regenerative cells from adipose tissue. All patents within the Company’s worldwide portfolio of issued and pending patent applications pertaining to the Celution^® technology are owned by Cytori and not affected by this decision.

Cytori Therapeutics

Cytori Therapeutics’ (NASDAQ:CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients’ adult stem and regenerative cells. The Celution(R) 800 System is being introduced in Europe into the reconstructive surgery market while the Celution(R) 900 System will be launched in Japan and Asia for cryopreserving a patient’s own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori Therapeutics’ Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Cytori Therapeutics
Tom Baker, 858-875-5258 (Media & Investors)
tbaker@cytoritx.com